Olfr303 Lentiviral Activation Particles (m): sc-434741-LAC
- Target species: mouse
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- Olfr303 Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- Olfr303 Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Olfr303 Lentiviral Activation Plasmid (m) and Olfr303 Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Olfr303 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Olfr303 Lentiviral Activation Particles (m) | sc-434741-LAC | 200 µl | $455.00 | |||
Olfr303 Lentiviral Activation Particles (m2) | sc-434741-LAC-2 | 200 µl | $455.00 |
Olfr303 encodes an olfactory receptor in mouse that belongs to the class A rhodopsin-like GPCR family and is predicted to couple odorant binding to heterotrimeric G protein signaling. Upon activation, olfactory receptors typically engage cAMP-mediated transduction cascades that regulate cyclic nucleotide-gated ion channels and downstream calcium-dependent neuronal responses, shaping sensory coding and behavioral outputs. Although Olfr303 is primarily studied in the context of olfaction, ectopic expression of olfactory receptors in non-olfactory tissues has been linked to broader GPCR-regulated processes, including modulation of cellular signaling states and chemotaxis-like responses. These features make Olfr303 relevant for investigating GPCR signaling logic, sensory neuron biology, and receptor deorphanization workflows.
Olfr303 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Olfr303 upregulation across a broader range of human cell types.
Olfr303 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Olfr303 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Olfr303 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Olfr303 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.